Emerging systemic pharmocologic approaches in acute respiratory distress syndrome

Respiratory Care Clinics of North America

Volumn 9, Issue 4, 2003, Pages 419-435

  Wiedemann, Herbert P ^a   Arroliga, Alejandro C ^a   Komara Jr , John J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 OXO 4 THIAZOLIDINECARBOXYLIC ACID; ACETYLCYSTEINE; ACTIVATED PROTEIN C; ATRIAL NATRIURETIC FACTOR; CELL ADHESION MOLECULE; DROTRECOGIN; IBUPROFEN; KETOCONAZOLE; LISOFYLLINE; METHYLPREDNISOLONE; PROSTAGLANDIN E1; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CORTICOSTEROID; DRUG DERIVATIVE; PENTOXIFYLLINE; PROTEIN C; RECOMBINANT PROTEIN;

BLEEDING; CLINICAL RESEARCH; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISABILITY; DRUG MECHANISM; DRUG METABOLISM; HUMAN; IN VITRO STUDY; LUNG INJURY; MUSCLE ATROPHY; MUSCLE WEAKNESS; PARESIS; PATHOPHYSIOLOGY; RESPIRATORY DISTRESS SYNDROME; REVIEW; TREATMENT OUTCOME; ADULT RESPIRATORY DISTRESS SYNDROME;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; ATRIAL NATRIURETIC FACTOR; HUMANS; KETOCONAZOLE; PENTOXIFYLLINE; PROTEIN C; RECOMBINANT PROTEINS; RESPIRATORY DISTRESS SYNDROME, ADULT;

EID: 0347589595     PISSN: 10785337     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-5337(03)00033-9     Document Type: Article

References (90)

1. Milberg JA, Davis DR, Steinberg KP, et al. Improved survival of patients with acute respiratory distress syndrome (ARDS): 1983-1993. JAMA 1995;273:306-9.
2. Anzueto A, Baughman RP, Guntupalli KK, et al. Aerosolized surfactant in sepsis-induced acute respiratory distress syndrome. N Engl J Med 1996;334:1417-21.
3. Artigas A, Bernard GR, Carlet J, et al. The American-European Conference on ARDS, part 2: ventilatory, pharmacologic, supportive therapy, study design strategies and issues related to recovery and remodeling. Intensive Care Med 1998;24:378-98.
4. Kollef MH, Schuster DP. The acute respiratory distress syndrome. N Engl J Med 1995;332:27-37.
5. Pittet JF, Mackersie RC, Martin RT, et al. Biological markers of acute lung injury: prognostic and pathogenetic significance. Am J Respir Crit Care Med 1997;155:1187-205.
6. Schuster DP. ARDS: clinical lesions from the oleic acid model of acute lung injury. Am J Respir Crit Care Med 1994;149:245-60.
7. Wiedemann HP, Matthay MA, Matthay RA, editors. Adult respiratory distress syndrome. Clin Chest Med 1990.
8. Komara JJ, Perez-Trepichio P, Wiedemann H. Systemic pharmacologic therapy of ARDS. Respir Care Clin 1998;4:739-50.
9. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl Med 2000;342:1334-49.
10. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
11. Matthay MA. Severe sepsis. A new treatment with both anticoagulant and antiinflammatory properties [editorial]. N Engl J Med 2001;344:759-62.
12. Manns BJ, Lee H, Doig CJ, et al. An economic evaluation of activated protein c treatment for severe sepsis. N Engl J Med 2002;347:993-1000.
13. Angus DC, Kinde-Zwirble W, Clermont G, et al. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit Care Med 2003;31:1-11.
14. Briegel J, Kellermann W, Forst H, et al. Low-dose hydrocortisone infusion attenuates the systemic inflammatory response syndrome. Clin Invest 1994;72:782-7.
15. Goldstein G, Luce JM. Pharmacologic treatment of the adult respiratory distress syndrome. Clin Chest Med 1990;11:773-87.
16. Meduri GU, Headley AS, Golden E, et al. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. JAMA 1998;280:159-65.
17. Jones RL, King EG. The effects of methylprednisolone on oxygenation in experimental hypoxemic respiratory failure. J Trauma 1975;15:297-303.
18. Bone RC, Fisher CJ, Clemmer TP, et al. Early methylprednisilone treatment for septic syndrome and the adult respiratory distress syndrome. Chest 1987;92:1032-6.
19. Luce JM, Montgomery AB, Marks JD, et al. Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. Am Rev Respir Dis 1998;138:62-8.
20. Sprung CL, Caralis PV, Marcial EH, et al. The effects of high-dose corticosteroids in patients with septic shock: a prospective controlled Study. N Engl J Med 1984:311:1137-43.
21. Veterans Administrative Systems Sepsis Cooperative Study Group. Effect of high dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med 1987;317:659-65.
22. Bernard GR, Luce JM, Sprung CL, et al. High-dose corticosteroids in patients with the adult respiratory distress syndrome. N Engl J Med 1987;317:1565-70.
23. Cronin L, Cook DJ, Carlet J, et at. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 1995;23:1430-9.
24. Lindeque BGP, Schoeman HS, Dommisse GF, et al. Fat embolism and the fat embolism syndrome: a double-blind therapeutic study. J Bone Joint Surg (Br) 1987;69B:128-31.
25. Schonfield SA, Polysongsang Y, DiLisio R, et al. Fat embolism prophylaxis with corticosteroids: prospective study in high-risk patients. Ann Intern Med 1983;99:438-43.
26. Masur H, Meier P, Mc Cutchan JA, et al. Consensus statement for use of corticosteroids as adjunctive therapy for pneumocystis pneumonia in AIDS. N Engl J Med 1990;323:1500-4.
27. Meduri GU, Belenchia JM, Estes RJ, et al. Fibroproliferative phase of ARDS: clinical findings and effects of corticosteroids. Chest 1991; 100:943-52.
28. Ashbaugh DG, Maier RV. Idiopathic pulmonary fibrosis in adult respiratory distress syndrome. Arch Surg 1985;120:530-5.
29. Hooper RG, Kearl RA. Established ARDS treated with sustained course of adrenocortical steroids. Chest 1990;97:138-43.
30. Brun-Buisson C, Brochard L. Corticosteroid therapy in acute respiratory distress syndrome: better late than never? JAMA 1998;280:182-3.
31. Hakkinen PJ, Schmoyer RE, Witschi HP. Potentiation of butylated-hydroxytoluene-induced acute lung damage by oxygen: effects of prednisolone and indomethacin. Am Rev Respir Dis 1983:128:648-51.
32. Hesterberg TW, Last JA. Ozone-induced acute pulmonary fibrosis in rats prevention of increased rates of collagen synthesis by methylprednisolone. Am Rev Respir Dis 1981;123:47-52.
33. Kehrer JP, Klein-Szanto AJP, Sorensen EMB, et al. Enhanced acute lung damage following corticosteroid treatment. Am Rev Respir Dis 1984;130:256-61.
34. Synder LS, Hertz MI, Harmon KR, et al. Failure of lung repair following acute lung injury: regulation of the fibroproliferative response (Parts 1 & 2). Chest 1990;98:733-8, 989-93.
35. Barber AE, Coyle SM, Marano MA, et al. Glucocorticoid therapy alters hormonal and cytokine responses to endotoxin in man. J Immunol 1993;150:1999-2006.
36. Donnelly SC, Strieter RM, Reid PT, et al. The association between mortality rates and decreased concentrations of interleukin-10 and interleukin-1 receptor antagonist in the lung fluids of patients with the adult respiratory distress syndrome. Ann Intern Med 1996;125:191-6.
37. Goodman RB, Strieter RM, Martin DP, et al. Inflammatory cytokines in patients with persistence of the acute respiratory distress syndrome. Am J Respir Crit Care Med 1996;154:602-11.
38. Meduri GU, Kohler G, Headley S, et al. Inflammatory cytokines in the BAL of patients with ARDS: persistent elevation over time predicts poor outcome. Chest 1995;108:1303-14.
39. Clark JG, Milberg JA, Steinberg KP, et al. Type III procollagen peptide in the adult respiratory distress syndrome: association of increased peptide levels in bronchoalveolar lavage fluid with increased of death. Ann Intern Med 1995;122:17-23.
40. Meduri GU, Headley S, Tolley E, et al. Plasma and BAL cytokine response to corticosteroid rescue treatment in late ARDS. Chest 1995:108:1315-25.
41. Meduri GU, Headley EA, Tolley A, et al. Plasma and BAL procollagen type I and III levels during ARDS and in response to prolonged methylprednisolone treatment [abstract]. Am J Respir Crit Care Med 1998;157:A460.
42. De Jonghe B, Sharshar T, Lefaucheur JP, et al. Paresis acquired in the intensive care unit. A prospective multicenter study. JAMA 2002; 2859-67.
43. Herridge MS, Cheung AM, Tansey CM, et al. One-year outcomes in survivors of the acute respiratory distress syndrome. N Engl J Med 2003;348:683-93.
44. Hyers TM, Tricomi SM, Dettenmeier PA, et al. Tumor necrosis factor levels in serum and bronchoalveolar lavage fluid of patients with the adult respiratory distress syndrome. Am Rev Respir Dis 1991:144:268-71.
45. Miller EJ, Cohen AB, Matthay MA. Increased interleukin-8 concentrations in the pulmonary edema fluid of patients with acute respiratory distress syndrome from sepsis. Crit Care Med 1996;24:1448-54.
46. Nhieu JTV, Misset B, Lebargy F, et al. Expression of tumor necrosis factor-α gene in alveolar macrophages from patients with the adult respiratory distress syndrome. Am Rev Respir Dis 1993;147:1585-9.
47. Raponi G, Antonelli M, Gaeta A, et al. Tumor necrosis factor in serum and in bronchoalveolar lavage of patients at risk for the adult respiratory distress syndrome. J Crit Care 1992;7:183-8.
48. Rinaldo JE, Christman JW. Mechanisms and mediators of the adult respiratory distress syndrome. Clin Chest Med 1990;11:621-32.
49. Fisher CJ, Dhainaut J-FA, Opal SM, et al. Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome: results from a randomized, double-blind, placebo-controlled trial. JAMA 1994;271:1836-43.
50. Opal SM, Fisher CJ, Dhainaut JF, et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized. double-blind, placebo-controlled, multicenter trial. Crit Care Med 1997;25:1115-24.
51. Yu M, Tomasa G. A double-blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome. Crit Care Med 1993;21:1635-44.
52. Bone RC. Modulators of coagulation: a critical appraisal of their role in sepsis. Arch Intern Med 1992;152:1381-9.
53. Hasegawa N, Husari AW, Hart WT, et al. Role of the coagulation system in ARDS. Chest 1994;105:268-77.
54. Slotman GJ, Burchard KW, D'Arezzo A, et al. Ketoconazole prevents acute respiratory failure in critically ill surgical patients. J Trauma 1988:28:648-54.
55. The ARDS Network. Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA 2000;283:1995-2002.
56. De Zeeuw D, Janssen WMT, de Jong PE. Atrial natriuretic factor: its pathophysiological significance in humans. Kidney Int 1992;41:1115-33.
57. Maack T. Receptors of atrial natriuretic factor. Annu Rev Physiol 1992;54:11-27.
58. Ruskoaho H. Atrial natriuretic peptide: synthesis, release, and metabolism. Pharmacol Rev 1992;44:479-602.
59. Tanabe M, Ueda M, Endo M, et al. The effect of atrial natriuretic peptide on pulmonary acid injury in a pig model. Am J Respir Crit Care Med 1996;154:1351-6.
60. Inomata N, Ohnuma N, Furuya M, et al. Alpha-human atrial natriuretic peptide (alpha-hANP) prevents pulmonary edema induced by arachidonic acid treatment in isolated perfused lung from guinea pig. Jpn J Pharmacol 1987;44(2):211.
61. Tanabe M, Ueda M, Endo M, et al. The effect of atrial natriuretic peptide on pulmonary acid injury in a pig model. Am J Respir Crit Care Med 1996;154:1351.
62. Kamiide Y, Hashino J, Hidaka T, et al. Anti-edema effect of SUN 4936 in a guinea pig model of LPS-induced acute lung injury. Suntory Report 1999.
63. Lordick F, Hauck RW, Senekowitsch R, et al. Atrial natriuretic peptide in acute hypoxia-exposed healthy subjects and in hypoxaemic patients. Eur Respir J 1995;8:216-21.
64. Westendorp RGJ, Roos AN, van der Hoeven JG, et al. Atrial natriuretic peptide improves pulmonary gas exchange in subjects exposed to hypoxia. Am Rev Respir Dis 1993;148:304-9.
65. The ARDS Clinical Trial Network. Randomized, placebo-controlled trial of lisofylline for early treatment of acute lung injury and acute respiratory distress syndrome. Crit Care Med 2002;30:1-6.
66. Tanabe M, Ueda M, Endo M, et al. Effect of acute lung injury and coexisting disorders on plasma concentration of atrial natriuretic peptide. Crit Care Med 1994;22:1762-8.
67. Mitaka C, Hirata Y, Nagura T, et al. Beneficial effect of atrial natriuretic peptide on pulmonary gas exchange in patients with acute lung injury. Chest 1998;114(1):223-8.
68. Clinical Investigators Brochure. 5th edition. Suntory Pharmaceutical; 2001.
69. Eison HB, Rosen MJ, Phillips RA, et al. Determinants of atrial natriuretic factor in the adult respiratory distress syndrome. Chest 1988;94:1040-5.
70. Mitaka C, Nagaura T, Sakanishi N, et al. Plasma alpha-atrial natriuretic peptide concentrations in acute respiratory failure associated with sepsis: preliminary study. Crit Care Med 1990;18:1201-3.
71. Leithner C, Frass M, Pacher R, et al. Mechanical ventilation with positive end-expiratory pressure decreases release of alpha-atrial natriuretic peptide. Crit Care Med 1987;15:484-8.
72. Bindels AJGH, van der Hoeven JG, Groeneveld PHP, et al. Atrial natriuretic peptide infusion and nitric oxide inhalation in patients with acute respiratory distress syndrome. Crit Care 2001;5:151-7.
73. George CLS, Fantuzzi G, Bursten S, et al. Effects of lisofylline on hyperoxia induced lung injury. Am J Physiol 1999;276:L776-85.
74. Guidot DM, Bursten SL, Rice GC, et al. Modulating phosphatidic acid metabolism decreases oxidative injury in rat lungs. Am J Physiol 1997;17:L957-66.
75. Hasegawa N, Oka Y, Nakayama M, et al. Effects of posttreatment with Lisofylline, a phosphatidic acid generation inhibitor, on septic acute lung injury in pigs. Am J Respir Crit Care Med 1997;155:928-36.
76. Abraham E, Bursten S, Shenkar R, et al. Phosphatidic acid signaling mediates lung cytokine expression and lung inflammatory injury following hemorrhage. J Exp Med 1995;181:569-75.
77. The ARDS Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000;342:1301-8.
78. Brigham KL. Role of free radicals in lung injury. Chest 1986;89:859-63.
79. Christman BW, Bernard GR. Antilipid mediator and antioxidant therapy in adult respiratory distress syndrome. New Horiz 1993;1:623-30.
80. Laurent T, Markert M, Feihl F, et al. Oxidant-antioxidant balance in granulocytes during ARDS: effect of N-acetylcysteine. Chest 1996;190:163-6.
81. 1 in patients with the adult respiratory distress syndrome. Chest 1989;96:114-9.
82. Pacht ER, Timerman AP, Lykens MG, et al. Deficiency of alveolar fluid glutathione in patients with sepsis and the adult respiratory distress syndrome. Chest 1991;100:1397-403.
83. Bernard GR, Swindell BB, Meredith MJ, et al. Glutathione (GSH) repletion by N-acetylcysteine (NAC) in patients with the adult respiratory distress syndrome (ARDS). Am Rev Respir Dis 1989;139:221A.
84. Domenighetti G, Suter PM, Scholler M-D, et al. Treatment with N-acetylcysteine during acute respiratory distress syndrome: a randomized, double-blind, placebo-controlled clinical study. J Crit Care 1997;12:177-82.
85. Bernard GR, Wheeler AP, Arons MM, et al. A trial of antioxidants N-acetylcysteine and Procysteine in acute respiratory distress syndrome. Chest 1997;112:164-72.
86. 1 and survival in patients with the adult respiratory distress syndrome: a prospective trial. Ann Surg 1986;203:371-8.
87. 1 in the adult respiratory distress syndrome. Chest 1990;97:684-92.
88. 1 in acute respiratory distress syndrome: a placebo-controlled, randomized, double-blind, multicenter clinical trial. Crit Care Med 1996;24:10-5.
89. 2 formation is increased in human sepsis syndrome: effects of cyclooxygenase inhibition. Am Rev Respir Dis 1991;144:1095-101.
90. Haupt M, Jastremski M, Clemmer T, et al. Effect of ibuprofen in patients with severe sepsis: a randomized double-blind multi-center study. Crit Care Med 1991;19:1339-47.